- Editas Medicine Inc (EDIT, Financial) sees a remarkable surge in Q1 revenue, up 308.8% year-over-year.
- Current analyst consensus rates Editas Medicine as a "Hold" with a notable potential upside.
- GuruFocus GF Value suggests a potential 70.13% increase from the current stock price.
Editas Medicine (EDIT) recently released its first-quarter earnings report, showcasing a GAAP EPS of -$0.92, which fell short of expectations by $0.35. Despite this earnings miss, the company reported a significant revenue increase of 308.8% year-over-year, reaching $4.66 million. This impressive revenue growth exceeded forecasts by $3.95 million.
Analyst Price Targets and Recommendations
According to the one-year price targets from eight analysts, Editas Medicine Inc (EDIT, Financial) is forecasted to reach an average target price of $4.00. This projection includes a high estimate of $8.00 and a low of $1.00, indicating a potential upside of 159.74% from the current stock price of $1.54. For more in-depth projections, visit the Editas Medicine Inc (EDIT) Forecast page.
Fifteen brokerage firms have contributed to Editas Medicine Inc's (EDIT, Financial) average recommendation score of 2.7, situating it within the "Hold" category. The rating scale spans from 1, indicating a Strong Buy, to 5, representing a Sell.
GuruFocus GF Value Insights
GuruFocus's estimates suggest that the GF Value for Editas Medicine Inc (EDIT, Financial) could reach $2.62 within a year. This implies a potential upside of 70.13% from the current trading price of $1.54. The GF Value reflects GuruFocus' assessment of the stock's fair trading value, derived from historical trading multiples, past business growth, and future business performance forecasts. For more comprehensive data, explore the Editas Medicine Inc (EDIT) Summary page.
